Over the past couple of weeks I've been looking into bio-tech companies to diversify my assets. Yesterday I stumbled on Exelixis becaue of a tumble (22%) they took after they did not end trials. Now like I said I'm new into the bio-tech field so my questions are thus:
What does it really mean that they didn't get out of trial staging early / are there many other competitors in the market that this delay will really effect.
What are the thoughts on a buy for long term at this stage?
Submitted March 27, 2014 at 02:07PM by andrewc8 http://ift.tt/1jSOizu
No comments:
Post a Comment